For the Inventor, By the Inventor

Enter assignee name

Glattpark, Switzerland

Baxalta Gmbh

USPTO Granted Patents = 151

CIPO Patents = 228

EPO Patents = 237

Trademarks = 57

Forward Citations = 469

Loading Chart...

Loading Chart...

455 inventors (with patents filed for the assignee):

Hans-Peter Schwarz (58 out of 105 patents)

Manfred Reiter (54 out of 71 patents)

Peter Turecek (52 out of 118 patents)

4. Friedrich Scheiflinger (46 out of 76 patents)

5. Leopold Grillberger (46 out of 42 patents)

6. Hanspeter Rottensteiner (34 out of 34 patents)

7. Wolfgang Mundt (32 out of 63 patents)

8. Wolfgang Teschner (30 out of 32 patents)

9. Michael Dockal (30 out of 31 patents)

10. Meinhard Hasslacher (29 out of 34 patents)

11. Artur Mitterer (23 out of 52 patents)

12. Alfred Weber (20 out of 27 patents)

13. Juergen Siekmann (20 out of 44 patents)

14. Friedrich Dorner (18 out of 91 patents)

15. Harald Arno Butterweck (16 out of 16 patents)

151 patents: Sort by Forward Citations

1. 11305000 - Chimeric OspA genes, proteins and methods of use thereof (2022-04-19),

2. 11081211 - Method and apparatus for providing a pharmacokinetic drug dosing regimen (2021-08-03),

3. 11020459 - Factor VIII formulations (2021-06-01),

4. 10934340 - Separation of VWF and VWF propeptide by chromatographic methods (2021-03-02),

5. 10905746 - Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF (2021-02-02),

6. 10900979 - Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD) (2021-01-26),

7. 10875906 - Removal of serine proteases by treatment with finely divided silicon dioxide (2020-12-29),

8. 10842853 - Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B (2020-11-24),

9. 10822394 - Method of producing recombinant high molecular weight vWF in cell culture (2020-11-03),

10. 10822376 - Biologically active peptides (2020-11-03),

11. D898342 - Carrying case (2020-10-13),

12. 10800816 - TFPI inhibitors and methods of use (2020-10-13),

13. 10772968 - Glycopolysialylation of non-blood coagulation proteins (2020-09-15),

14. 10758599 - Stabilized liquid and lyophilized ADAMTS13 formulations (2020-09-01),

15. 10745672 - Method of producing a polypeptide or virus of interest in a continuous cell culture (2020-08-18),

Baxalta GmbH is a global biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare and chronic diseases. With a focus on improving patients' lives, Baxalta discovers, manufactures, and markets a wide range of biologic medicines, vaccines, and hematology products. They are dedicated to advancing science and finding innovative solutions to address unmet medical needs around the world.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

151 Patents

#2 in Glattpark

#113 in Switzerland

#5,257 in the World

Glattpark, Switzerland

Baxalta Gmbh

Forward Citations = 469

455 inventors:

Hans-Peter Schwarz (58 out of 105 patents)

Manfred Reiter (54 out of 71 patents)

Peter Turecek (52 out of 118 patents)

4. Friedrich Scheiflinger (46 out of 76 patents)

5. Leopold Grillberger (46 out of 42 patents)

Please report any incorrect information to support@idiyas.com

Loading…